CryoLife's Second Annual Surgical Congress for the Ross Procedure to Draw More than 130 Cardiovascular Surgeons from Around...(for use in cardiac and vascular surgerie...)

Date:9/3/2009

for use in cardiac and vascular surgeries throughout the U.S. and Canada. The Company's CryoValve(R) SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft(R) technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed or malfunctioning native or prosthetic pulmonary valves. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company's BioFoam(R) Surgical Matrix is CE marked in the European Community for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical. BIOGLUE Aesthetic(TM) Medical Adhesive is CE marked in the European Community for periosteal fixation following endoscopic browplasty (brow lift) in reconstructive plastic surgery and is distributed by a third party for this indication. CryoLife distributes HemoStase(TM), a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the European Community and Canada for cardiac, vascular, and general surgery, subject to certain exclusions.

Statements made in this press release or in the embedded video that look forward in time or that express management's beliefs, expectations or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include those regarding the expected increases in the number of Ross Procedures, expected mortality rates of patients undergoing the Ross Procedure with an experienced surgeon, expected incidents of surgical reinterventions in patients undergoing the Ross Procedure, and expected increased support for better survival rates for patients u
'/>"/>

SOURCE CryoLife, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. ACD Completes the Second Closing of Series A Financing and Initiates Services for Biomarker Validation and Companion Diagnostic Development
2. NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate
3. avVaa World Health Care Products, Inc. Announces the completion of its first week of DRTV 120/60 second test commercials for Neuroskin(R) Psoriasis Relief
4. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
5. Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing
6. Encorium Reports Second Quarter 2009 Financial Results
7. Los Gatos Research Introduces Second Generation Liquid-Water Isotope Analyzer
8. Spherix Reports Second Quarter 2009 Earnings
9. Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results
10. NovaBay Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results
11. China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results